Good podcast? Give it some love!
Blood Advances Talks
Blood Advances TalksEpisodes
Blood Advances Talks
Blood Advances Talks
A Science podcast
Good podcast? Give it some love!
Rate Podcast
Episodes of Blood Advances Talks
Mark All
Search Episodes...
Big data are used in the pursuit of precision medicine in the general population. Applying these tools to patients with sickle cell disease (SCD) is essential for ensuring that they receive the most appropriate customized therapy for their dise
Sickle cell disease (SCD) is an inherited blood condition resulting from abnormal hemoglobin production. It is one of the most common genetic diseases in the world. The clinical manifestations are variable and range from recurrent acute and deb
The prospect of a clinical strategy using an adeno-associated virus (AAV) vector for expression of therapeutic levels of factor VIII (FVIII) has been highly desirable. This was initially anticipated by promising data from clinical studies on AA
The availability of novel nonfactor therapeutics is revolutionizing the management of hemophilia in individuals with inhibitory antibodies, as well as making prophylaxis more convenient even in the absence of inhibitors. Unfortunately, the use
Amy Shapiro discusses the recent approval of concizumab for the treatment of patients with hemophilia. This novel subcutaneous homeostatic rebalancing agent has proven to be useful for the treatment of patients with hemophilia A and B, and we h
Allogeneic hematopoietic stem cell transplantation (HCT) is curative in many patients with advanced hematopoietic malignancies. Donor T cells not only facilitate engraftment and protect against opportunistic pathogens and residual disease, but
The high incidence of thromboembolic disease, and in particular venous thromboembolism (VTE), has emerged as an important consideration in hospitalized and critically ill patients with coronavirus disease 2019 (COVID-19).
The treatment of hemophilia, which has undergone many transformative changes over the past 60 years, is poised for yet another disruptive change: the use of gene therapy to produce functional cures in some persons with hemophilia A or B.
The changing landscape of anticoagulation in cancer-associated thrombosis
TA-TMA: state of the art for diagnosis and treatment by Blood Advances Talks
Inherited predisposition to myeloid malignancies by Blood Advances Talks
Managing patients who are receiving warfarin (or DOAC)and need an elective surgery or procedure by Blood Advances Talks
Daily light-and-darkness onset regulates mouse hematopoietic stem cells by Blood Advances Talks
Extended therapy for unprovoked venous thromboembolism: when is it indicated? by Blood Advances Talks
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances by Blood Advances Talks
Challenges facing the benign hematology physician-scientist workforce by Blood Advances Talks
Choosing for whom to recommend allogeneic transplantation for AML in CRL by Blood Advances Talks
Catalyzing innovation in clinical trial design and analysis at NHLBI by Blood Advances Talks
ITP and thrombosis: an intriguing association by Blood Advances Talks
The current therapeutic landscape of FLT3 inhibitors by Blood Advances Talks
How many mice? Design considerations for murine studies by Blood Advances Talks
The Direct Oral Anticoagulants – can we finally stop using rat poison? by Blood Advances Talks
Impact of the ICAL on the treatment of acute leukemia by Blood Advances Talks
Technological Solutions For Global Hematology And Oncology by Blood Advances Talks
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us